Last Update 26 Mar 26

QDEL: Lifotronic Supply Agreement And Reimbursement Shift Will Shape Future Upside

QuidelOrtho's consensus analyst price target has been adjusted to $34.67. Analysts point to a slightly higher discount rate, modestly lower profit margin assumptions and a higher future P/E multiple as they factor in recent reimbursement policy commentary and mixed target moves from UBS, JPMorgan and Citi.

Analyst Commentary

Recent research highlights a mix of supportive and cautious views on QuidelOrtho, with target price changes and reimbursement policy headlines feeding into updated valuation work.

Bullish Takeaways

Bullish analysts backing higher target prices point to room for a higher future P/E multiple, implying they see the current valuation as leaving upside if execution stays on track.
Target raises from large banks such as JPMorgan and Citi suggest some confidence that QuidelOrtho can manage through recent reimbursement debate and still support earnings power over time.
The consensus target of $34.67 already reflects mixed target moves, yet higher individual targets indicate a camp of investors willing to ascribe a premium for the company’s diagnostics footprint.
Supportive views see recent headlines as more of a factor in discount rates and scenario analysis rather than a thesis breaker, keeping the long term growth case intact in their models.

Bearish Takeaways

Bearish analysts trimming targets highlight a slightly higher discount rate, signaling increased perceived risk around policy, pricing and reimbursement visibility.
The draft shift in China toward analyte based, method agnostic reimbursement is seen as a potential headwind that could narrow the economic advantage of dry chemistry, which feeds into more conservative margin assumptions.
Modestly lower profit margin assumptions in updated models reflect concern that reimbursement changes and competitive dynamics may cap earnings leverage relative to earlier expectations.
Mixed target moves, including both raises and cuts, underscore that execution on pricing, product mix and cost control needs to be closely watched before assigning a consistently higher valuation multiple.

What's in the News

QuidelOrtho entered a long term supply agreement with Lifotronic Technology to broaden its global immunoassay portfolio, gaining access to multiple analyzer platforms and a menu of more than 70 assays, including over 25 not currently available on the VITROS system, across select markets outside the United States (Key Developments).
The Lifotronic agreement is planned to help QuidelOrtho compete for full menu tenders and reach a wider range of lab settings, from smaller low volume labs to high throughput environments that require scalable capacity and broad test menus (Key Developments).
QuidelOrtho announced that Chief Financial Officer Joseph M. Busky plans to retire effective June 30, 2026, with a successor search underway and Busky staying on in an advisory role to support the transition (Key Developments).
The company issued earnings guidance for fiscal 2026, with expected total revenue in the range of US$2.7b to US$2.9b (Key Developments).

Valuation Changes

Fair Value: Consensus fair value remains unchanged at $34.67 per share.
Discount Rate: The discount rate has risen slightly from 11.77% to 12.33%, reflecting a modestly higher required return in current models.
Revenue Growth: The revenue growth assumption is effectively unchanged at about 3.32%.
Net Profit Margin: The net profit margin assumption has eased slightly from 13.33% to about 13.08%.
Future P/E: The future P/E multiple has risen modestly from about 8.32x to about 8.61x, indicating a slightly higher valuation being applied to expected earnings.

12 views

Key Takeaways

Expansion into global and underpenetrated markets, alongside demographic trends, positions QuidelOrtho for sustained diagnostic demand and stable long-term revenue streams.
Operational efficiency, high-value diagnostics innovation, and improved customer satisfaction enhance margins, market share, and resilience against future industry challenges.
Post-pandemic demand decline, product discontinuations, regional pricing pressures, integration challenges, and lagging innovation threaten revenue, margins, and competitive positioning.

Catalysts

About QuidelOrtho

Provides diagnostic testing solutions.What are the underlying business or industry changes driving this perspective?

Expansion into international markets such as Latin America, Asia Pacific, and underpenetrated regions like China-where differentiated technology, low market share, and a large runway for immunoassay growth exist-positions QuidelOrtho to capture increased demand stemming from global health system focus on early detection and public health surveillance, which should drive topline revenue growth.
Acquisition of LEX Diagnostics and the planned commercialization of its rapid molecular point-of-care platform addresses the trend toward fast, decentralized testing and is likely to increase recurring revenues and enhance margins as high-value, high-velocity diagnostic solutions become more prevalent.
Demographic shifts, including an aging global population and increasing prevalence of chronic and lifestyle diseases, support baseline volume growth in key QuidelOrtho diagnostic platforms spanning clinical chemistry, immunoassays, and molecular diagnostics, underpinning long-term, stable revenue streams.
Continued operational improvements-such as indirect procurement cost reductions, manufacturing site consolidation, and successful ERP system integration-are yielding significant margin and EBITDA gains, with incremental savings expected to directly benefit net margins and EPS into 2026 and beyond.
Strong and improving customer satisfaction, recognized by top service rankings, and strategic talent acquisition in regulatory affairs are likely to support customer loyalty and regulatory execution, helping defend and expand market share, thus providing resilience and future upside potential to earnings.

QuidelOrtho Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming QuidelOrtho's revenue will grow by 3.3% annually over the next 3 years.
Analysts are not forecasting that QuidelOrtho will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate QuidelOrtho's profit margin will increase from -41.5% to the average US Medical Equipment industry of 13.1% in 3 years.
If QuidelOrtho's profit margin were to converge on the industry average, you could expect earnings to reach $393.9 million (and earnings per share of $5.67) by about March 2029, up from -$1.1 billion today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 8.7x on those 2029 earnings, up from -1.0x today. This future PE is lower than the current PE for the US Medical Equipment industry at 27.6x.
Analysts expect the number of shares outstanding to grow by 0.67% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 12.33%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Post-pandemic normalization is creating persistent drag on QuidelOrtho's revenues and profit margins, with COVID-related revenue falling sharply (COVID testing revenue down 52% YoY, and 2025 full year COVID guidance reduced by $40 million) and no new expected drivers to offset this high-margin product line; this directly threatens both top-line revenue and net margins.
The winding down and discontinuation of certain product lines-such as the Donor Screening business and the Savanna molecular platform (which triggered $150 million in non-cash charges and eliminates future cash flows from those assets)-highlights risks in portfolio concentration and product obsolescence, ultimately reducing future revenue diversification and potentially impacting future earnings and profitability.
Shifts in healthcare purchasing behavior in key international markets, particularly China, including volume-based procurement (VBP), reimbursement changes, and potential panel unbundling (DRG) processes, pose ongoing risks of price erosion and volume pressure; while the company claims limited near-term impact, further expansion in China may be constrained by these secular and regulatory headwinds, risking long-term revenue and margin growth in that region.
Execution risk from large-scale integrations (such as the ongoing integration of Ortho Clinical and planned acquisition of LEX Diagnostics) could lead to elevated costs, operational disruptions, or delays in achieving anticipated synergies; additional restructuring charges and slow synergy realization may compress margins and negatively impact net earnings.
Intensifying industry competition and rapid shifts toward decentralized, point-of-care, and next-generation diagnostic technologies may outpace QuidelOrtho's current R&D and platform upgrades (evidenced by recent product discontinuations and reliance on yet-to-be-approved new platforms like LEX), increasing the risk of market share loss, revenue declines, and the need for higher R&D spending that weighs on overall profitability.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $34.67 for QuidelOrtho based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $50.0, and the most bearish reporting a price target of just $25.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $3.0 billion, earnings will come to $393.9 million, and it would be trading on a PE ratio of 8.7x, assuming you use a discount rate of 12.3%.
Given the current share price of $16.01, the analyst price target of $34.67 is 53.8% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on QuidelOrtho?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Global Expansion And Decentralized Testing Will Unlock Future Potential